

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anaesthetics and muscle relaxants											
Bupivacaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cisatracurium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etidocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Halothane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Remifentanyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rocuronium	▲	▲	▲	▲	◆	◆	◆	◆	▲	▲	◆
Sevoflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Analgesics											
Acetoclofenac	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alfentanil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aspirin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Buprenorphine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Dexketoprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextropropoxyphene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diamorphine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diclofenac	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diflunisal	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydrocodeine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etoricoxib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl (Prescribed)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flurbiprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocodone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydromorphone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibuprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indometacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Meloxicam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metamizole (Dipyrone)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metadone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Morphine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naproxen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefopam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxycodone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Paracetamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piroxicam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tramadol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anthelmintics											
Albendazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxamniquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Praziquantel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyrantel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antiarrhythmics											
Amiodarone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bepriidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Digoxin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disopyramide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dronedarone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flecainide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mexiletine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propafenone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vernakalant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Antibacterials											
Amikacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aztreonam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bedaquiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benzylpenicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezlotoxumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefaclor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefadroxil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefradine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftaroline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloramphenicol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clarithromycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clavulanic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clofazimine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Daptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Delamanid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erythromycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethambutol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linezolid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lymecycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methenamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norfloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillin V	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pivmecillinam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pretomanid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyrazinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifampicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifapentine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifaximin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telithromycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Temocillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticarcillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Troleandomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

◆	These drugs should not be coadministered
▲	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anticoagulant, anti-platelet and fibrinolytic											
Abciximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acenocoumarol	■	■	■	■	■	■	■	■	■	■	◆
Anagrelide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Apixaban	▲	▲	▲	▲	■	■	◆	◆	▲	▲	◆
Caplacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Dabigatran	■	■	●	■	■	■	◆	◆	■	●	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Edoxaban	■	■	■	■	■	■	◆	◆	■	●	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluidione	◆	◆	■	◆	■	■	◆	◆	■	■	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	■	■	■	■	■	■	◆	◆	■	■	◆
Prasugrel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rivaroxaban	■	■	■	■	●	●	◆	◆	■	■	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	■	■	■	■	●	●	◆	◆	■	■	◆
Ticlopidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Warfarin	■	■	■	■	■	■	◆	◆	■	■	◆
Anticonvulsants											
Carbamazepine	■	●	■	■	●	●	●	■	■	●	◆
Clonazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eslicarbazepine	■	●	■	■	●	●	●	■	■	●	◆
Ethosuximide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	■	●	■	■	●	●	●	■	■	●	◆
Perampanel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenobarbital	■	●	■	■	●	●	●	■	■	●	◆
Phenytoin	◆	●	◆	◆	●	●	●	■	■	●	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	■	●	■	■	●	●	●	■	■	●	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anticonvulsants continued											
Rufinamide	■	■	■	■	■	■	●	■	■	■	◆
Sodium valproate	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valproate semisodium	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Valproic acid (Divalproex)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants											
Agomelatine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Dosulepin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mianserin	◆	▲	▲	◆	■	■	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefazodone	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenelzine	●	●	●	●	●	●	●	●	●	●	●
Reboxetine	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Tianeptine	◆	■	■	■	■	■	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised February 2025. Full information available at www.hep-druginteractions.org

Page 4 of 6

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anxiolytics/hypnotics/sedatives											
Alprazolam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Amobarbital	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bromazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bromperidol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Buspirone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clobazam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clorazepate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clotiapine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Diazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Estazolam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Flurazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lorazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lormetazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Midazolam (oral)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Midazolam (parenteral)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Oxazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Quazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Temazepam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Triazolam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Zaleplon	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Zolpidem	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Zopiclone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Beta Blockers											
Atenolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bisoprolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carvedilol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Celiprolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Labetalol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Metoprolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nebivolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Oxprenolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pindolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Propranolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sotalol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Timolol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bisphosphonates											
Alendronic acid	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clodronate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ibandronic acid	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pamidronate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Risedronate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Zoledronic acid	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bronchodilators											
Acidinium bromide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Formoterol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Indacaterol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ipratropium bromide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Montelukast	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Omalizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Reslizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Salbutamol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Salmeterol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Theophylline	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tiotropium	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Umeclidinium bromide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vilanterol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Calcium channel blockers											
Amlodipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Diltiazem	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Felodipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nicardipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nifedipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nisoldipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nitrendipine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Verapamil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Cancer Therapies											
Abiraterone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Acalabrutinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Afatinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Alectinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Alpelisib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Amivantamab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Anastrozole	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Apalutamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Asciminib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Asparaginase	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Atezolizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Avapritinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Avelumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Axitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Azacitidine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Belantamab mafodotin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bendamustine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bevacizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bexarotene	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bicalutamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Blinatumomab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bortezomib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bosutinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brentuximab vedotin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Capecitabine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carboplatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carfilzomib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cemiplimab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cetuximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Chlorambucil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cisplatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cyclophosphamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Daratumumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dasatinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dinutuximab beta	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Doxorubicin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Durvalumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Erlotinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Elotuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Elranatamab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Enzalutamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Eporitamab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Epirubicin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Estramustine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etoposide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Everolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Exemestane	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fluorouracil (5-FU)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fludarabine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gefitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gemcitabine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gemtuzumab ozogamicin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Glofitamab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

For personal use only. Not for distribution.

Key to symbols

♦	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised February 2025. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r +DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Cancer Therapies continued											
Hydroxyurea (Hydroxycarbamide)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ibrutinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Idarubicin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Idelalisib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Imatinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Inotuzumab ozogamicin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ipilimumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Irinotecan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Isatuximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ixazomib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lapatinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Letrozole	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Loncastuximab tesirine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Medroxyprogesterone (oncology)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mercaptopurine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mesna	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Methotrexate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mitoxantrone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mogamulizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nilotinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Niraparib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nivolumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Obinutuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ofatumumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Olaparib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Olaratumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Osimertinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Oxaliplatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Paclitaxel	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Panitumumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Panobinostat	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pertuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pomalidomide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ponatinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ramucirumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Retifanlimab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Rituximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ruxolitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sacituzumab govitecan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sunitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tamoxifen	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tegafur/Gimeracil/Oteracil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Temsirolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tepotinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tisotumab vedotin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tivozanib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Topotecan (oral)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trametinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trastuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trastuzumab deruxtecan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trastuzumab emtansine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Trifluridine/tipiracil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vinblastine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vincristine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vinorelbine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Contraceptives and hormone replacement											
Conjugated Estrogens	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Desogestrel (POP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Desogestrel/ethinylestradiol (COC) (>20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Desogestrel/ethinylestradiol (COC) (≤20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dienogest	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Drospirenone (POP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Drospirenone/estradiol (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Drospirenone/Ethinylestradiol (COC) (>20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Drospirenone/Ethinylestradiol (COC) (≤20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dydrogesterone/estradiol (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ethinylestradiol (>20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ethinylestradiol (≤20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etonogestrel (implant)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etonogestrel (vaginal ring)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gestodene/ethinylestradiol (COC) (>20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gestodene/ethinylestradiol (COC) (≤20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel (Emergency Contraception)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel (implant)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel (IUD)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel (POP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel/ethinylestradiol (COC) (>20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Levonorgestrel/ethinylestradiol (COC) (≤20 µg)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Medroxyprogesterone (depot)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Medroxyprogesterone (oral)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Medroxyprogesterone/conjugated estrogens (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Medroxyprogesterone/estradiol (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Micronized progesterone (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norelgestromin/ethinylestradiol (patch)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norethisterone (Norethindrone) (depot injection)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norethisterone (Norethindrone) (POP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norethisterone (Norethindrone)/estradiol (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norethisterone (Norethindrone)/ethinylestradiol (COC)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norethisterone (Norethindrone)/mestranol (COC)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norgestimate/ethinylestradiol (COC)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norgestrel/conjugated estrogens (HRT)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Norgestrel/ethinylestradiol (COC)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Testosterone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Erectile dysfunction agents											
Sildenafil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tadalafil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vardenafil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Yohimbine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

For personal use only. Not for distribution.

Key to symbols

♦	These drugs should not be coadministered
♦	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
♦	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
♦	No clinically significant interaction expected

Notes

- > Further information is available at www.hep-druginteractions.org
- > Predicted interactions are based on known metabolic pathways and routes of clearance.
- > Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- > Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised February 2025. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r +DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Gastrointestinal agents											
Aluminium hydroxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alverine citrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aprepitant	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Cimetidine	▲	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Cisapride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Droperidol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Famotidine	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Granisetron	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lafutidine	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Linacotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macrogol	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nizatidine	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Omeprazole	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
Ranitidine	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Roxatidine	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimebutine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vonoprazan	◆	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆
HCC Therapies											
Atezolizumab + bevacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenvatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pembrolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Regorafenib	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Sorafenib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis B Drugs											
Adefovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2b	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis C Directly Acting Antivirals (DAAs)											
Daclatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elbasvir/Grazoprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
OBV/PTV/r	◆	◆	◆	◆	◆	n/a	◆	◆	◆	◆	◆
OBV/PTV/r + DSV	◆	◆	◆	◆	n/a	◆	◆	◆	◆	◆	◆
Ravidasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis D Directly Acting Antivirals (DAAs)											
Bulevirtide	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r +DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Herbals/Supplements/Vitamins											
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enteric feeds	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginger (Z. officinale)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goldenseal (H. canadensis)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Green tea (C. sinensis)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kava kava	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Menthol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mucuna pruriens	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridoxine (Vitamin B6)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Saw Palmetto (S. repens)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
St John's wort	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
THC capsules	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

◆	These drugs should not be coadministered
▲	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
HIV Drugs											
<i>Entry/Integrase Inhibitors</i>											
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/ABC/3TC	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elvitegravir/cobi/FTC/TDF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enfuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	◆	▲	▲	▲	▲	▲	▲	▲	◆	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NNRTIs</i>											
Dapivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Efavirenz	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etravirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nevirapine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine/dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Didanosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF (TDF)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>Protease Inhibitors</i>											
Atazanavir alone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir/cobicistat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir + ritonavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir/cobicistat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosamprenavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indinavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lopinavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ritonavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tipranavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Hypertension/heart failure agents											
Acebutolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bosentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorthalazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clevipidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Irbesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isradipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivabradine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilmenidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sildenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spirolactone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Torasemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

◆	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Illicit/Recreational											
Alcohol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Amphetamine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bromazolam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cannabis	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carfentanil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cocaine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ecstasy (MDMA)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etizolam	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fentanyl (Recreational)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
GHB (Gamma-hydroxybutyrate)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Heroin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
LSD (Lysergic acid diethylamide)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mephedrone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Methamphetamine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nicotine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Nitazenes	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Phencyclidine (PCP)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Xylazine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Immunosuppressants											
Abatacept	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Adalimumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Alemtuzumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Anakinra	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Azathioprine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Baricitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Basiliximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Belimumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bimekizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brodalumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Canakinumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ciclosporin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cladribine (oral)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ecilizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etanercept	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fingolimod	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Golimumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Guselkumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Infliximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ixekizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lenalidomide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mirikizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mycophenolate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pirfenidone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ravulizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Risankizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sarilumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Secukinumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sirolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Siltuximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tacrolimus	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tildrakizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tocilizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tralokinumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ublituximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Upadacitinib	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ustekinumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Vedolizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lipid Lowering Agents											
Alirocumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Atorvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bempedoic acid	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bezafibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Evolocumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ezetimibe	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fenofibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fish oils	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fluvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gemfibrozil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Icosapent ethyl	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lovastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Omega-3-6-9 fatty acids	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pitavastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pravastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Rosuvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Simvastatin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs											
Acamprosate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Acetazolamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Acitretin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Activated charcoal	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Allopurinol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Atomoxetine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Atropine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Baclofen	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bamlanivimab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Benralizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Betahistine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bimatoprost	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Biperiden	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brimonidine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brinzolamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brolucizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Bromocriptine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Burosumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Calcitonin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Calcium carbimide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Calcium resonium	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cannabidiol (CBD)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carbamazole	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carisoprodol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Casirivimab/imdevimab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cilostazol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Clomifene	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Colchicine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Colestyramine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Conivaptan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Convalescent plasma (COVID-19)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
COVID-19 vaccines	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Crizanlizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cyclobenzaprine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cyproterone acetate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Cytisine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Darbepoetin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Deferiprone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Denosumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dexamfetamine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dextromethorphan	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Disulfiram	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Donepezil	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dorzolamide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dupilumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Eliglustat	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Emicizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Epoetin alfa	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etelcalcetide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Faricimab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Febuxostat	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Filgrastim	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Flibanserin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Gadopentetate (gadolinium)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Glucose monohydrate (IV)	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Glycerol phenylbutyrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Goserelin acetate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Guanfacine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Idarucizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Influenza vaccine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦

For personal use only. Not for distribution.

Key to symbols

♦	These drugs should not be coadministered
♦	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
♦	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
♦	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised February 2025. Full information available at www.hep-druginteractions.org

Page 9 of 6

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs continued											
Interferon beta	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanadelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	▲	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lofexidine	▲	▲	◆	◆	▲	◆	◆	◆	◆	◆	◆
Lumacaftor/vacaftor	●	●	●	●	●	●	●	●	●	●	●
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	■	●	■	■	■	■	■	■	■	■	◆
Nafidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Penicillamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Romosozumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Sodium zirconium cyclosilicate	◆	◆	◆	▲	▲	▲	▲	▲	▲	▲	▲
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Oxytocics											
Ergometrine (ergonovine)	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Mifepristone	▲	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents											
Benzotropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
PBC Agents											
Obeticholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids											
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone ≤16 mg	◆	◆	◆	◆	■	■	●	◆	◆	◆	◆
Dexamethasone >16 mg	■	■	◆	◆	■	■	◆	◆	■	■	◆
Fludrocortisone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Urological Agents											
Alfuzosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	▲	◆	◆	■	■	◆	◆	◆	◆	◆
Silodosin	■	■	■	■	■	■	◆	◆	■	■	◆
Solifenacin	◆	▲	▲	◆	■	■	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.